Aruni Ghose: Our review delves into the progress across urological malignancies and discusses future directions in ADC development
Aruni Ghose, Internal Medicine Resident at Barts Health NHS Trust,
“Pleasure to First Author this with wonderful students Patricia Lapitan, Vedika Apte, Abhinav Kandala, Sreejana Basu, Adheesh Ghosh, pharmacist Jo Parkes, scientist Sayali Shinde, senior urologic oncologists Professor Nikhil Vasdev, Professor Stergios Boussios, Anand Sharma, Prantik Das and the International Urology Cancer Summit team – Sara Elena Rebuzzi, Yüksel Ürun, Ravindran Kanesvaran, Akash Maniam, and Giuseppe Banna.
Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody drug conjugate (ADC) development, emphasising their transformative potential in cancer care.
ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges.”
Proceed to the article.
Source: Aruni Ghose/LinkedIn
An antibody-drug conjugate (ADC) is a type of targeted cancer therapy. The concept behind ADCs is to specifically deliver cytotoxic drugs to cancer cells while sparing normal cells, thus potentially reducing side effects compared to traditional chemotherapy. The antibody component targets the cancer cell, the ADC is internalized by the cell, and once inside, the cytotoxic drug is released, killing the cancer cell. Enfortumab vedotin, which was mentioned earlier, is an example of an ADC used in the treatment of certain types of cancer, such as urothelial cancer.